Back to News
Market Impact: 0.25
SciSparc Ltd. Subsidiary NeuroThera Labs Reports Progress in Phase IIb Clinical Trial for Tourette Syndrome
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
SciSparc said subsidiary NeuroThera Labs completed manufacturing its investigational product and received batch release certification from a European Qualified Person. The certification authorizes shipment; the article gives no financial figures or additional details on the product or shipment.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
SPRC0.65
More News
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage
- Apple’s $2,000 iPhone Duo Debuts With Limited Supply
- Boeing 777 freighter output halted for two months over supplier row
- Exclusive-Boeing supplier dispute has halted 777 freighter production for two months, sources say
- OpenAI Trims Target Value & Volvo Cars Cuts 2,500 Jobs
- Kinder Morgan, Energy Transfer and Williams could benefit from cheap natural gas